Smartest Doc
Paternal exposure to methotrexate and pregnancy outcomes
The Journal of Rheumatology, 01/18/2011
Clinical Article
Beghin D et al. – Based on our results and case reports in literature, paternal MTX exposure at the time of conception does not seem to raise any major concern for offspring.
Methods- Used prospective data of our Teratology Information Service
- Analyzed outcomes of paternal MTX exposure at time of conception or up to 3 months before conception
- Report on outcomes of 42 pregnancies involving 40 men treated with MTX at time of conception
- 23 men were treated for an inflammatory disease (54.8%), 9 for psoriasis (21.4%), and 8 for malignant disease (19.0%)
- Weekly dosages varied between 7.5 mg and 30 mg
- Pregnancies resulted in 36 live births, 3 spontaneous abortions, and 3 voluntary abortions
- No congenital malformation observed at birth
